Kinarus Receives Grant of Key U.S. Patent for its Lead Therapeutic Candidate
Kinarus Receives Grant of Key U.S. Patent for its Lead Therapeutic Candidate
- Kinarus Receives Grant of Key U.S. Patent for its Lead Therapeutic Candidate
Grant of KIN001 composition of matter patent strengthens proprietary position in U.S. until at least 2037
Basel, Switzerland, April 26, 2022. - Kinarus AG ('Kinarus') announced today that the United States Patent and Trademark Office (USPTO) has issued US Patent No.
- 11285155 entitled "Pharmaceutical Combinations for Treating Cancer" that covers the Kinarus lead therapeutic candidate KIN001.
- Kinarus' differentiated therapeutic candidate, KIN001, has broad potential in numerous therapeutic areas.